Clinical Trials Browser

NCT06233942 2026-03-18

Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors

Phase 1 Recruiting

308 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT06248411 2026-03-18

A Clinical Study of KK2260 in Patients With Advanced or Metastatic Solid Tumors

Phase 1 Recruiting

189 enrolled

Other solid neoplasm

Advanced or Metastatic Solid Tumors

NCT06585488 2026-03-18

A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification

Phase 1 Recruiting

514 enrolled

GastrointestinalOther solid neoplasmThoracic

Metastatic Solid Tumors

NCT05155332 2026-03-17

A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)

Phase 1 Recruiting

190 enrolled

Other solid neoplasm

Solid Tumors

NCT06927297 2026-03-17

Phase I Study of the Safety, Tolerability, and Efficacy of an Engineered Mitochondrial Vaccine in Advanced Solid Tumors

Phase 1 Recruiting

12 enrolled

Other solid neoplasm

Advanced Solid Tumor Malignancies

NCT06960395 2026-03-17

Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Phase 1 Recruiting

450 enrolled

Other solid neoplasm

Solid Tumor Malignancies

NCT07477743 2026-03-17

A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combinations in Advanced Solid Tumors

Phase 1 Recruiting

331 enrolled

Other solid neoplasm

Advanced Solid Tumor Cancer

NCT05957536 2026-03-13

A Study of D3L-001 as Monotherapy in Subjects With HER2-Positive Advanced Solid Tumors

Phase 1 Recruiting

128 enrolled

Other solid neoplasm

HER-2 Positive Advanced Solid Tumors

NCT06307795 2026-03-13

A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors

Phase 1 Recruiting

63 enrolled

Other solid neoplasm

Locally Advanced or Metastatic Solid Tumors

NCT06892379 2026-03-13

A Study of HS-20110 in Participants With Advanced Solid Tumors

Phase 1 Recruiting

475 enrolled

Other solid neoplasm

Solid Tumors

NCT07207707 2026-03-13

A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies

Phase 1 Recruiting

78 enrolled

Other solid neoplasm

Solid Tumor Malignancies

NCT07223125 2026-03-13

A Study of JNJ-89862175 for Treatment of Advanced Solid Tumors

Phase 1 Recruiting

360 enrolled

Other solid neoplasm

Advanced-stage Solid Tumors

NCT05238792 2026-03-12

Multi Tumor-Associated Antigen-Specific T Lymphocytes to Treat Patients With High Risk Solid Tumors

Phase 1 Recruiting

36 enrolled

Other solid neoplasm

Solid Tumor

NCT06563375 2026-03-12

Phase 1 Dose Escalation and Dose Expansion Trial of NP-101 in Patients With Solid Tumors

Phase 1 Recruiting

35 enrolled

Other solid neoplasm

Solid Tumor

NCT06598800 2026-03-12

Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors

Phase 1 Recruiting

87 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT07372625 2026-03-12

A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.

Phase 1 Recruiting

14 enrolled

Other solid neoplasm

TP53 Y220C Mutation

NCT06234397 2026-03-11

Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid Tumors

Phase 1 Recruiting

245 enrolled

Other solid neoplasm

Advanced or Metastatic Solid Tumors

NCT07141706 2026-03-09

A Study of DB-1317 in Selected Advanced/Metastatic Solid Tumors

Phase 1 Recruiting

233 enrolled

Other solid neoplasm

Advanced/Metastatic Solid Tumors

NCT05661201 2026-03-06

NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors

Phase 1 Recruiting

24 enrolled

Other solid neoplasm

Solid Tumor

NCT06031441 2026-03-06

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Phase 1 Recruiting

250 enrolled

Other solid neoplasm

Locally Advanced Solid Tumors

NCT07189949 2026-03-06

A Study of HRS-2329 in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications

Phase 1 Recruiting

120 enrolled

Other solid neoplasm

Advanced Solid Tumors Harboring RAS Mutations or Amplifications

NCT04928508 2026-03-05

Okgyn1

Phase 1 Recruiting

50 enrolled

Other solid neoplasm

Solid Tumor, Adult

NCT06596473 2026-03-05

A Study of BG-C477 in Participants With Advanced Solid Tumors

Phase 1 Recruiting

310 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT05981703 2026-03-04

A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors

Phase 1 Recruiting

217 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT06589596 2026-03-04

An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors

Phase 1 Recruiting

244 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT07387068 2026-03-04

Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants With Advanced Solid Tumors

Phase 1 Recruiting

121 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT05873686 2026-03-03

A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers

Phase 1 Recruiting

140 enrolled

GenitourinaryOther solid neoplasmThoracic

Adenocarcinoma, Carcinoma, Carcinoma, Non-Small-Cell Lung, Kidney Neoplasms, Mesothelioma, Neoplasms

NCT06573294 2026-03-03

Trial to Assess the Safety and Antitumor Activity of GEN1057 in Malignant Solid Tumors

Phase 1 Recruiting

45 enrolled

Other solid neoplasm

Advanced Malignant Solid Tumors

NCT06994806 2026-03-03

A Study to Investigate the Safety and Efficacy of KQB168 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

Phase 1 Recruiting

84 enrolled

Other solid neoplasm

Solid Tumor Malignancies

NCT07446816 2026-03-03

A Clinical Study Evaluating the Preliminary Anti-tumor Efficacy and Safety of Hemay181

Phase 1 Recruiting

24 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT06612645 2026-03-02

CMD03

Phase 1 Recruiting

9 enrolled

Other neoplasmOther solid neoplasm

Pediatric Cancers

NCT04855656 2026-02-27

MYTHIC

Phase 1 Recruiting

464 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT06402201 2026-02-27

First in Human Study of CDR404 in HLA-A*02:01 Participants With MAGE-A4 Expressing Solid Tumors

Phase 1 Recruiting

42 enrolled

Other solid neoplasm

Select Advanced Solid Tumors

NCT06659341 2026-02-27

A Phase I Study of BAY3498264 Given Together With Sotorasib in Participants Who Have Advanced Solid Cancers With Specific Genetic Changes Called KRASG12C Mutation

Phase 1 Recruiting

104 enrolled

Other solid neoplasm

Advanced Solid Tumors Harboring KRAS G12C Mutation

NCT07204340 2026-02-27

TLN-372 in Advanced KRAS Mutant Solid Tumors

Phase 1 Recruiting

240 enrolled

Other solid neoplasm

KRAS Mutant Solid Tumors

NCT07030959 2026-02-25

Study of AUBE00 in Patients With Solid Tumors

Phase 1 Recruiting

130 enrolled

Other solid neoplasm

Solid Tumors

NCT07108114 2026-02-23

SLV-324 Treatment of Metastatic Solid Tumors

Phase 1 Recruiting

70 enrolled

Other solid neoplasm

Metastatic Solid Tumors

NCT07181681 2026-02-23

A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors

Phase 1 Recruiting

63 enrolled

Other solid neoplasm

Solid Tumors

NCT06265688 2026-02-20

First In Human Study of CX-2051 in Advanced Solid Tumors

Phase 1 Recruiting

160 enrolled

Other solid neoplasm

Solid Tumor, Adult

NCT06625593 2026-02-20

A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors

Phase 1 Recruiting

168 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT06566079 2026-02-17

Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors

Phase 1 Recruiting

100 enrolled

Other solid neoplasmThoracic

Mesothelioma, Malignant, Neoplasm Metastasis

NCT06885697 2026-02-17

Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma

Phase 1 Recruiting

100 enrolled

GastrointestinalGynecologicOther solid neoplasmThoracic

Colonic Neoplasms, Lung Neoplasms, Mesothelioma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Thymoma, Thymus Neoplasms

NCT07123103 2026-02-17

A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors

Phase 1 Recruiting

150 enrolled

Other solid neoplasm

Solid Tumors

NCT05067283 2026-02-12

KANDLELIT-001

Phase 1 Recruiting

830 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT06750185 2026-02-11

Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors

Phase 1 Recruiting

39 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT07252479 2026-02-11

Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations

Phase 1 Recruiting

91 enrolled

Other solid neoplasm

Solid Tumors (Phase 1)

NCT05568680 2026-02-10

SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma

Phase 1 Recruiting

42 enrolled

GynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Ovarian Neoplasms

NCT05620017 2026-02-09

Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8008 for Injection

Phase 1 Recruiting

182 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT05701527 2026-02-05

A Study of EBC-129 in Advanced Solid Tumours

Phase 1 Recruiting

98 enrolled

Other solid neoplasm

Advanced Solid Tumours

NCT06480552 2026-02-05

An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

Phase 1 Recruiting

240 enrolled

Other solid neoplasm

Advanced Solid Tumors